Short‐term safety of an anti‐severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study

BACKGROUND: Since 2020, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become prevalent worldwide. In severe cases, the case fatality rate is high, and vaccine prevention is important. This study evaluated the safety of receiving SARS‐CoV‐2 vaccine in patients with advanced lung ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Tomoki, Ninomiya, Kiichiro, Kubo, Toshio, Kuyama, Shoichi, Tachibana, Sayaka, Inoue, Koji, Chikamori, Kenichi, Kudo, Kenichiro, Ochi, Nobuaki, Harada, Daijiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807248/
https://www.ncbi.nlm.nih.gov/pubmed/34964270
http://dx.doi.org/10.1111/1759-7714.14281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807248/
https://www.ncbi.nlm.nih.gov/pubmed/34964270
http://dx.doi.org/10.1111/1759-7714.14281

Ejemplares similares